2 / 4
Notes:
conference
series LLC Ltd
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
Page 26
Debabrata (Dev)Mukhopadhyay, Clin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-028
Anti-angiogenesis therapy and Immune crosstalk: Clinical conundrums
and optimisms
A
ngiogenesis, the formation of new capillaries, is an essential process in many
physiological and pathological events. In cancers, new vasculature promotes tumor
growth and metastasis. Vascular permeability factor/vascular endothelial growth factor
(VPF/VEGF) has been implicated in the new vessel development found in most tumors
including GI related tumors, renal cell carcinoma, brain cancer and also hematological
malignancies. Several groups including ours have been investigating decades regarding the
regulatory role of VPF/VEGF to elucidate the mechanisms by which this important pro-
angiogenesis cytokine functions in a variety of tumor models. Based on those studies there
are several anti-angiogenesis drugs are now in clinics to treat cancer patients and other
vascular diseases. However, our recent experiences in clinics and also results from different
laboratories suggest that therapy with anti-angiogenesis drugs frequently does not extend
survival of cancer patients for more than months, because tumors elicit elusive resistance.
In addition, some reports propose that VEGF inhibitors reduce primary tumor growth but
promote tumor invasiveness and metastasis. On the other hand, like angiogenesis, escaping
immune destruction is also an important hallmark for cancer progression and metastasis.
Currently several immune checkpoint inhibitors have been approved by FDA to treat
different type of cancer patients however there are several gaps need to fill in related to the
basic understanding of those inhibitors’ function that might improve the overall clinical
outcome. Recent works suggest that VEGF is one of the factors playing a key role of the
success of the immune therapy. In this regard, the current lecture will focus how immune
therapy can cross talk with VEGF pathways and some thoughts regarding new direction of
anti-angiogenesis therapy and anti-tumor immune escape and selective targeting to best
treat cancer patients in the near future.
Biography
Debabrata Mukhopadhyay is a Professor of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, has
a joint appointment with the Department of Physiology and Biomedical Engineering and Associate Director of Mayo
Clinic Comprehensive Cancer Center for Global Alliances. He has a broad background in tumor microenvironment,
with specific training and expertise in key research areas including Cancer, Cardiovascular Diseases, and Diabetes.
As a Post-doctoral fellow, later as an Independent Investigator followed by as an Associate Professor at Harvard
Medical School, Boston, he carried out angiogenesis and tumor microenvironment related research. After moving to
Mayo Clinic as a Professor and also as Directors of both Tumor Microenvironment and Nanomedicine programs, he
has been supervising additional research areas including stellate cell biology, new drug delivery systems and trained
several young investigators who are now independent faculties in different institutes. Recently, he has received
a Tumor Microenvironment Training Grant (T32) from National Cancer Institute. Additionally, he has initiated the
biannual Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium, which has been widely attended by
international and national scientists and also Mayo Clinic and University of Minnesota Nanotechnology workshops.
He has been serving as reviewer for several study sections in NIH, and also international funding agencies and also
participating as Editorial Board Member of well received journals including
Cancer Research and Nanomedicine
mukhopadhyay.debabrata@mayo.eduDebabrata (Dev)
Mukhopadhyay
Mayo Clinic College of Medicine and Science
USA